Written by Timm Hoeres, Markus Horneber and the CAM-Cancer Consortium.
Updated July 13, 2016


Evidence tables

Please view the PDFs listed below for details uncontrolled clinical trials included in this summary.

* uncontrolled trials on DCA for cancer

Citation Timm Hoeres, Markus Horneber, CAM-Cancer Consortium. Dichloroacetate [online document]. http://ws.cam-cancer.org/The-Summaries/Dietary-approaches/Dichloroacetate. July 13, 2016.


  1. BG Chemie. Toxikologische Bewertung: Dichloressigsäure, Natriumdichloracetat. Toxikologische Bewertungen - Ausgabe 03/06 Nr. 188b, 1-138. 2006.
  2. Ammini, C. V. & Stacpoole, P. W. Biotransformation, Toxicology and Pharmacogenomics of Dichloroacetate. In : Gribble, G. W. (ed.), Naturally Occurring Organohalgoen Compounds – a Comprehensive Update. Berlin: Springer Verlag,  2003, pp. 215-34.
  3. Michelakis, E. D., Webster, L. & Mackey, J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008;99:989-94.
  4. Stacpoole, P. W., Nagaraja, N. V. & Hutson, A. D. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003;43:683-91.
  5. Chinnery, P., Majamaa, K., Turnbull, D. & Thornburn, D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006;1:CD004426.
  6. Stacpoole, P. W., Henderson, G. N., Yan, Z., Cornett, R. & James, M. O. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 1998;30:499-539.
  7. Agbenyega T, et al. Population kinetics, efficacy, and sadfety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol 2003;43:386-96.
  8. Kankotia, S. and P. W. Stacpoole. Dichloroacetate and cancer: new home for an orphan drug? Biochim Biophys Acta 2014;1846:617-29.
  9. Shroads, A. L. et al. Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity. J Pharmacol Exp Ther 2008;324:1163-71.
  10. Shroads, A. L., T. Langaee, B. S. Coats, T. L. Kurtz, J. R. Bullock, D. Weithorn, Y. Gong, D. A. Wagner, D. A. Ostrov, J. A. Johnson and P. W. Stacpoole . Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol 2012;52:837-49.
  11. Michelakis, E. D. et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:1-7.
  12. James, MO & Stacpoole, PW. Pharmacogenetic considerations with dichloroacetate dosing. Pharmacogenomics 2016;17:743-53.
  13. Gorsky D. The latest chapter in the seemingly never-ending saga of dichloroacetate as a cancer treatmenthttps://www.sciencebasedmedicine.org/the-latest-chapter-in-the-seemingly-never-ending-saga-of-dichloroacetate-as-a-cancer-treatment/ (accessed on May 30, 2016)
  14. Geddes, L. Do-it-yourself Chemotherapy Access. Cancer World November/December, 2007;38-42.
  15. Warburg, O., Posener, K. & Negelein, E. Über den Stoffwechsel der Carcinomzelle. Biochem Ztschr 1924;152:309-44.
  16. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
  17. Kim, J. W. & Dang, C. V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-30.
  18. Mathupala, S. P., Ko, Y. H. & Pedersen, P. L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 2009;19:17-24.
  19. U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals (http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm [accessed on May 30, 2016].
  20. Garon, E. B., H. R. Christofk, W. Hosmer, C. D. Britten, A. Bahng, M. J. Crabtree, C. S. Hong, N. Kamranpour, S. Pitts, F. Kabbinavar, C. Patel, E. von Euw, A. Black, E. D. Michelakis, S. M. Dubinett and D. J. Slamon. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.  J Cancer Res Clin Oncol 2014;140:443-52.
  21. Chu, Q. S., R. Sangha, J. Spratlin, J. V. L, J. R. Mackey, A. J. McEwan, P. Venner and E. D. Michelakis. A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors." Invest New Drugs 2015;33:603-10.
  22. Dunbar, E. M., B. S. Coats, A. L. Shroads, T. Langaee, A. Lew, J. R. Forder, J. J. Shuster, D. A. Wagner and P. W. Stacpoole. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 2014;32:452-64.
  23. Strum, S. B., O. Adalsteinsson, R. R. Black, D. Segal, N. L. Peress and J. Waldenfels. "Case report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP." J Bioenerg Biomembr 2013;45:307-15.
  24. Flavin, D. Medullary thyroid carcinoma relapse reversed with dichloroacetate: A case report. Oncol Lett 2010;1:889-91.
  25. Flavin, D. F. Non-Hodgkin's Lymphoma Reversal with Dichloroacetate. Volume 2010, Article ID 414726, 4 pages.
  26. Khan A. Use of oral dichloroacetate for palliation of leg pain arising from metastatic poorly differentiated carcinoma: a case report. J Palliat Med 2011;14:973-7.
  27. Calvert, L. D. et al. Dichloroacetate enhances performance and reduces blood lactate during maximal cycle exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1090-4.
  28. Stacpoole, P. W. et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006;117:1519-31.
  29. Fox, A. W. et al. Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J Pharmacol Exp Ther 1996;279:686-93.
  30. Krishna, S. et al. Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. QJM 1995;88:341-9.
  31. Theodoratos, A. et al. Phenylalanine-induced leucopenia in genetic and dichloroacetic acid generated deficiency of glutathione transferase Zeta. Biochem Pharmacol 2009;77:1358-63.
  32. Stacpoole, P. W., Kurtz, T. L., Han, Z. & Langaee, T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 2008;60:1478-87.
  33. Kaufmann, P. et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;66:324-30.
  34. Brandsma, D., Dorlo, T. P., Haanen, J. H., Beijnen, J. H. & Boogerd, W. Severe encephalopathy and polyneuropathy induced by dichloroacetate. J Neurol 2010;257:2099-100.
  35. Felitsyn, N., Stacpoole, P. W. & Notterpek, L. Dichloroacetate causes reversible demyelination in vitro: potential mechanism for its neuropathic effect. J Neurochem 2007;100:429-36.
  36. Heshe, D. et al. Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother Pharmacol 2011;67:647-55.
  37. Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 1989;38:1124-44.